December 02, 2020
Home  »  Website  »  National  »  Psoriasis Injection Okayed For Limited Use To Treat Covid Patients: Drug Controller

Psoriasis Injection Okayed For Limited Use To Treat Covid Patients: Drug Controller

The approval was given after its clinical trials on Covid-19 patients in India was found satisfactory by the expert committee, an official said.

Google + Linkedin Whatsapp
Follow Outlook India On News
Psoriasis Injection Okayed For Limited Use To Treat Covid Patients: Drug Controller
Representational image
Psoriasis Injection Okayed For Limited Use To Treat Covid Patients: Drug Controller
outlookindia.com
2020-07-11T08:06:13+05:30

India's drug regulator has approved Itolizumab, a drug used to cure skin ailment psoriasis for "restricted emergency use" to treat COVID-19 patients with moderate to severe acute respiratory distress, officials said.

Considering the unmet medical needs to treat COVID-19, Drugs Controller General of India, Dr V G Somani, approved monoclonal antibody injection Itolizumab, an already approved drug of Biocon, for restricted emergency use for the treatment of ‘cytokine’ release syndrome in moderate to severe acute respiratory distress syndrome patients due to COVID-19, they said.

"The approval was given after its clinical trials on COVID-19 patients in India was found satisfactory by the expert committee comprising pulmonologists, pharmacologists and medicine experts from AIIMS, among others, for treatment of cytokine release syndrome,” an official told PTI.

"It is already an approved drug of Biocon for treating psoriasis for the last many years," the official said.

Written informed consent of each patient is required before the use of this drug, he said.


For in-depth, objective and more importantly balanced journalism, Click here to subscribe to Outlook Magazine
Next Story >>
Google + Linkedin Whatsapp

The Latest Issue

Outlook Videos